Review says PANoptosis could become a new drug target across disease areas

A new review in Cancer Biology & Medicine argues that PANoptosis links several programmed cell-death pathways into one upstream control point with major implications for infection, inflammation and cancer. The authors say the field now needs biomarkers, local delivery strategies and safety data before PANoptosis can be translated into precision medicine.

Why it matters: - PANoptosis could give researchers a single therapeutic handle on cell-death pathways that often compensate for one another. - The review says that could matter in infectious, autoimmune, neurodegenerative, cardiovascular and cancer settings where cell death drives either tissue damage or immune defense. - A clearer PANoptosis strategy could help turn mixed death signaling from a drug-development obstacle into a treatment target.

What happened: - Researchers from The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University and Jiaying University published a review in Cancer Biology & Medicine. - The review has DOI 10.20892/j.issn.2095-3941.2026.0012. - The article examines PANoptosis and the PANoptosome, a multiprotein platform that coordinates pyroptosis, apoptosis and necroptosis. - The review also covers five PANoptosome types built around Z-DNA binding protein 1 (ZBP1), absent in melanoma 2 (AIM2), receptor-interacting serine/threonine-protein kinase 1 (RIPK1), NOD-like receptor family pyrin domain containing 12 (NLRP12) and NOD-like receptor family CARD domain containing 5 (NLRC5). - The source URL is the published review.

The details: - PANoptosis is described as an integrated form of programmed cell death that combines features of pyroptosis, apoptosis and necroptosis. - The review frames PANoptosis as a supercomplex rather than a coincidence of three separate death programs. - The PANoptosome follows a sensor–adaptor–catalytic architecture. - Sensor proteins detect pathogen-associated molecular patterns and damage-associated molecular patterns. - Adaptor proteins such as apoptosis-associated speck-like protein containing a CARD and Fas-associated protein with death domain connect the signal. - Catalytic effectors including caspase-8, caspase-1 and receptor-interacting serine/threonine-protein kinase 3 carry out cell death. - AIM2- and NLRP12-driven complexes favor pyroptosis through caspase-1 and gasdermin D. - RIPK1- and NLRC5-driven complexes tend to lean toward apoptosis and necroptosis. - ZBP1-linked signaling is described as more balanced across death outputs. - Mitochondrial outer membrane permeabilization, mitochondrial reactive oxygen species and mitochondrial DNA release can amplify PANoptosome assembly. - Tumor necrosis factor-alpha, interferon-gamma, metabolic reprogramming and post-translational modifications can shift the death outcome. - In cancer, acute PANoptosis may release damage signals and strengthen antitumor immunity. - Chronic low-level PANoptosis can instead support inflammation, immunosuppression and tumor progression.

Between the lines: - The review argues that one-pathway inhibition often fails because cells can route around blocked apoptosis, pyroptosis or necroptosis. - That makes PANoptosome components attractive upstream targets, but also raises safety concerns because broad activation could trigger inflammatory damage. - The paper suggests the field is moving from describing PANoptosis to designing ways to control it. - The authors say the next step is to identify biomarkers, determine which PANoptosome dominates in each disease and develop local delivery systems. - The review says no validated PANoptosis biomarker exists yet, which is a major barrier to patient selection and clinical use. - The authors also note that broad PANoptosis induction could release large amounts of damage-associated molecular patterns and cytokines.

What's next: - Researchers are testing small-molecule inhibitors aimed at NLRP3, RIPK1, ZBP1 and caspases in preclinical or early clinical settings. - Nanomedicines and combination therapies are being explored to improve precision and reduce toxicity. - The review points to immune checkpoint inhibitors, photodynamic therapy and oncolytic viruses as combination approaches under study. - In inflammatory, autoimmune, neurodegenerative and cardiovascular diseases, the therapeutic goal is to dampen PANoptosis and protect tissue. - In cancer, the goal is often to induce PANoptosis, especially in tumors that resist apoptosis. - Clinical translation will depend on better detection tools, patient stratification and safety studies.

The bottom line: - PANoptosis looks like a promising but difficult precision-medicine target, with the biggest near-term hurdle being how to control it without unleashing harmful inflammation.